Francis Eko to Immunity, Mucosal
This is a "connection" page, showing publications Francis Eko has written about Immunity, Mucosal.
Connection Strength
1.017
-
Pais R, Omosun Y, Igietseme JU, Fujihashi K, Eko FO. Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses. Front Immunol. 2019; 10:1577.
Score: 0.698
-
Zuo Z, Zou Y, Li Q, Guo Y, Zhang T, Wu J, He C, Eko FO. Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge. Sci Rep. 2021 05 17; 11(1):10389.
Score: 0.199
-
Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vaccines. 2003 Feb; 2(1):45-51.
Score: 0.056
-
He Q, Martinez-Sobrido L, Eko FO, Palese P, Garcia-Sastre A, Lyn D, Okenu D, Bandea C, Ananaba GA, Black CM, Igietseme JU. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines. Immunology. 2007 Sep; 122(1):28-37.
Score: 0.019
-
Igietseme J, Eko F, He Q, Bandea C, Lubitz W, Garcia-Sastre A, Black C. Delivery of Chlamydia vaccines. Expert Opin Drug Deliv. 2005 May; 2(3):549-62.
Score: 0.016
-
Igietseme JU, Eko FO, He Q, Bandea C, Black CM. Developing effective delivery systems for Chlamydia vaccines. Curr Opin Mol Ther. 2004 Apr; 6(2):182-94.
Score: 0.015
-
Igietseme JU, Eko FO, Black CM. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev Vaccines. 2003 Feb; 2(1):129-46.
Score: 0.014